LLM 2021 | BTKi discontinuation in CLL: intolerance & disease progression
Neil Kay, MD, Mayo Clinic, Rochester, MN, talks on discontinuation of Bruton’s tyrosine kinase inhibitors (BTKi) for intolerance and disease progression in patients with chronic lymphocytic leukemia (CLL). Although some patients discontinue BTKi for persistently bothersome, but not life-threatening, adverse events, there also are significant adverse events such as hypertension and atrial fibrillation. BTKi intolerance has been evaluated extensively, with evidence suggesting that intolerance, rather than progression, can be a dominant reason for discontinuation, particularly of ibrutinib. This interview took place at the Lymphoma, Leukemia & Myeloma Congress 2021.
Disclosures
Advisory Board for: Abbvie, Astra Zeneca, Beigene, Behring, Cytomx Therapy, Dava Oncology, Janssen, Juno Theraputics, Oncotracker, Pharmacyclics and Targeted Oncology. DSMC (Data Safety Monitoring Committee) for: Agios Pharm, AstraZeneca, BMS –Celgene, Cytomx Therapeutics, Janssen, Morpho-sys, Rigel. Research funding from: Abbvie, Acerta Pharma, Bristol Meyer Squib, Celgene, Genentech, MEI Pharma, Pharmacyclics, Sunesis, TG Therapeutics, Tolero Pharmaceuticals.
